ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 8, 2007 - AVANIR
Pharmaceuticals (NASDAQ:AVNR) today announced Phase III data on the
efficacy, safety and improvements in patient-centered outcomes in
patients with diabetic peripheral neuropathic (DPN) pain treated
with the investigational drug Zenvia(TM) (dextromethorphan /
quinidine) will be presented in two scientific posters at the
Second International Congress on Neuropathic Pain, being held in
Berlin, Germany on June 7 to 10, 2007.

Both posters will be presented at Poster Session 1: Clinical -
Pharmacotherapy on Friday, June 8, 2007, between 1:30 p.m. and 3:30
p.m. Central European time (CET).

"This scientific congress serves as a showcase for new
developments in pain treatment. We are pleased that these data have
been recognized as important by the congress organizers and
accepted for presentation," said Randall Kaye, MD, Chief Medical
Officer of AVANIR Pharmaceuticals.

On April 18, 2007 AVANIR Pharmaceuticals announced positive
top-line results from a Phase III study of Zenvia in patients with
DPN pain. In the trial, two doses of Zenvia, 45/30 mg DMQ dosed
twice daily (DMQ 45) and 30/30 mg DMQ dosed twice daily (DMQ 30),
were compared to placebo based on daily patient diary entries for
the Pain Rating Scale, which was the primary endpoint as defined in
the Special Protocol Assessment (SPA) with the U.S. Food and Drug
Administration (FDA). Both Zenvia treatment groups had lower pain
rating
s than placebo patients (p less than or equal to 0.0001 in
both cases). In this study, Zenvia also demonstrated statistically
significant improvements in a number of key secondary endpoints
including the Pain Relief Ratings Scale and the Pain Intensity
Ratings Scale. Although not statistically powered to detect
differences in the secondary endpoint of Peripheral Neuropathy
Quality of Life Scale Composite score, the DMQ 45 patients showed a
greater improvement than placebo patients (p=0.05) and the DMQ 30
patients showed a greater improvement than placebo patients
(p=0.08). Overall, the safety data from this study were consistent
with data from previous studies. The most commonly reported adverse
events were dizziness, nausea, diarrhea, fatigue and somnolence and
were mild to moderate in nature. A higher number of patients in the
DMQ 45 and DMQ 30 treatment groups (25.2% and 21.0%, respectively)
discontinued due to an adverse event than compared to placebo
(11.4%). There were no significant differences in serious adverse
events with 7.6%, 4.8% and 4.1% reported in the DMQ 45, DMQ 30 and
placebo groups, respectively and no deaths occurred during the
study.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the
therapeutically active ingredient dextromethorphan, and the enzyme
inhibitor quinidine, which serves to increase the bioavailability
of dextromethorphan. This first-in-class drug candidate is believed
to help regulate excitatory neurotransmission in two ways, through
pre-synaptic inhibition of glutamate release via sigma-1 receptor
agonist activity, and through postsynaptic glutamate response
modulation via uncompetitive, low-affinity NMDA antagonist
activity. Zenvia is currently in development for the treatment of
Involuntary Emotional Expression Disorder (IEED) and DPN pain.

In October 2006, the Company received an approvable letter for
the treatment of Zenvia in IEED. To address safety concerns raised
in the FDA's a
pprovable letter for Zenvia for the treatment of
IEED, the company intends to initiate a confirmatory Phase III
study with a new lower quinidine dose formulation of Zenvia. In
April 2007 AVANIR completed the first of two planned Phase III
studies in diabetic peripheral neuropathic pain where all primary
endpoints were successfully met. The Company is considering whether
it would be necessary or advisable to study a similar lower dose of
quinidine in the second Phase III trial being planned for DPN
pain.

About AVANIR

AVANIR Pharmaceuticals is focused on developing, acquiring and
commercializing novel therapeutic products for the treatment of
chronic diseases. AVANIR's products and product candidates address
therapeutic markets that include the central nervous system,
cardiovascular disorders, inflammation and infectious diseases.
AVANIR currently markets FazaClo(R), the only orally-disintegrating
formulation of clozapine for the management of severely ill
schizophrenic patients who fail to respond adequately to standard
drug treatments for schizophrenia. FazaClo is also indicated for
reducing the risk of suicidal behavior in patients with
schizophrenia or schizoaffective disorder. For full prescribing
information and important safety information regarding FazaClo,
please visit www.fazaclo.com, AVANIR's lead product candidate for
the treatment of involuntary emotional expression disorder (IEED),
Zenvia, is the subject of an approvable letter from the FDA.
Additionally, AVANIR recently completed a Phase III clinical trial
with Zenvia in patients with diabetic peripheral neuropathic (DPN)
pain where all primary endpoints were met. AVANIR has an ongoing
development program with Novartis International Pharmaceutical Ltd.
for the treatment of inflammatory disease. The Company's first
commercialized product, Abreva(R), is marketed in North America by
GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores
. Further
information about AVANIR can be found at www.avanir.com.

Forward-Looking Statement

Statements in this press release that are not historical facts,
including statements that are preceded by, followed by, or that
include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," or similar statements, are
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the future results expressed or implied by such statements.
There can be no assurance that the Company will receive FDA
regulatory approval for Zenvia or that the additional development
work for Zenvia will be completed in the time periods that are
anticipated. Final review decisions made by the FDA and other
regulatory agencies concerning are often unpredictable and outside
the influence and control of the Company. Risks and uncertainties
also include the risks set forth in AVANIR's most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q,
and from time-to-time in other publicly available information
regarding the Company. Copies of this information are available
from AVANIR upon request. AVANIR disclaims any intent to update
these forward-looking statements.

To be included on AVANIR's e-mail alert list; click on the link
below or visit AVANIR's website:
http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...

(Date:12/8/2016)... TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...

(Date:12/8/2016)... , Dec. 8, 2016 Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...

(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...